Daré Bioscience, Inc. (DARE)
NASDAQ: DARE · Real-Time Price · USD
1.980
-0.040 (-1.98%)
At close: Jun 15, 2026, 4:00 PM EDT
1.982
+0.002 (0.08%)
After-hours: Jun 15, 2026, 7:42 PM EDT
Daré Bioscience Employees
As of December 31, 2025, Daré Bioscience had 24 total employees, including 21 full-time and 3 part-time employees. The number of employees increased by 1 or 4.35% compared to the previous year.
Employees
24
Change (1Y)
1
Growth (1Y)
4.35%
Revenue / Employee
$48,218
Profits / Employee
-$500,869
Market Cap
29.66M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 24 | 1 | 4.35% | 21 | 3 |
| Dec 31, 2024 | 23 | -3 | -11.54% | 21 | 2 |
| Dec 31, 2023 | 26 | -4 | -13.33% | 23 | 3 |
| Dec 31, 2022 | 30 | 2 | 7.14% | 25 | 5 |
| Dec 31, 2021 | 28 | 5 | 21.74% | 20 | 8 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Aligos Therapeutics | 82 |
| Evaxion | 46 |
| Senti Biosciences Holdings | 39 |
| Kyntra Bio | 34 |
| Boundless Bio | 28 |
| Actinium Pharmaceuticals | 25 |
| Lisata Therapeutics | 21 |
| INmune Bio | 21 |
DARE News
- 4 days ago - Daré Bioscience Transcript: AGM 2026 - Transcripts
- 14 days ago - Daré Bioscience Proxy statement: Proxy filing - Filings
- 14 days ago - Daré Bioscience Proxy statement: Proxy filing - Filings
- 20 days ago - Dare Bioscience receives NIH funding award notice to advance DARE-HPV - TheFly
- 20 days ago - Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-HPV, its Novel Investigational Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer - GlobeNewsWire
- 4 weeks ago - Dare Bioscience initiates DARE-HPV clinical study - TheFly
- 4 weeks ago - Daré Bioscience Initiates Phase 2 Study of DARE-HPV, a Novel Pharmacologic Treatment for Persistent High-Risk HPV Infection with No FDA-Approved Therapies - GlobeNewsWire
- 4 weeks ago - Daré Bioscience Earnings Call Transcript: Q1 2026 - Transcripts